PMID- 32898507
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1872-6240 (Electronic)
IS  - 0006-8993 (Linking)
VI  - 1748
DP  - 2020 Dec 1
TI  - Tibolone regulates systemic metabolism and the expression of sex hormone 
      receptors in the central nervous system of ovariectomised rats fed with high-fat 
      and high-fructose diet.
PG  - 147096
LID - S0006-8993(20)30454-6 [pii]
LID - 10.1016/j.brainres.2020.147096 [doi]
AB  - Estrogen replacement therapy decreases some risk factors of the metabolic 
      syndrome but increases the risk of some types of cancer. Tibolone (TIB) has shown 
      similar neuroprotective effects as estrogens. This study aimed to evaluate the 
      effects of TIB on metabolic parameters and the expression of sex hormone 
      receptors in the CNS in ovariectomised rats fed with a hypercaloric diet. 
      Sprague-Dawley female rats were ovariectomised and fed for 30 days with a 
      standard diet (SD) or high-fat high-fructose diet (HFFD) and treated with TIB 
      (1 mg/kg) or vehicle. At the end of the treatments, HFFD increased body weight, 
      glucose tolerance, triglycerides and cholesterol levels, while TIB treatment 
      decreased these parameters. Subsequently, the hippocampus, the hypothalamus and 
      the frontal cortex were dissected. RT-PCR was performed for progesterone receptor 
      (PR), androgen receptor (AR), estrogen receptors alpha and beta (ERalpha, ERbeta), 
      insulin receptor (IR) and insulin-like growth factor 1 (IGF-1). HFFD altered the 
      expression of sex hormone receptors in specific brain structures involved in the 
      regulation of homeostasis and cognition, which highlights the importance of a 
      healthy diet. In turn, TIB modulated the expression of these receptors, 
      particularly in the hypothalamus.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Coyoy-Salgado, Angelica
AU  - Coyoy-Salgado A
AD  - Catedras CONACyT-Unidad de Investigacion Medica en Enfermedades Neurologicas, 
      Hospital de Especialidades Dr. Bernardo Sepulveda, Centro Medico Nacional Siglo 
      XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
FAU - Segura-Uribe, Julia J
AU  - Segura-Uribe JJ
AD  - Unidad de Investigacion Medica en Enfermedades Neurologicas, Hospital de 
      Especialidades Dr. Bernardo Sepulveda, Centro Medico Nacional Siglo XXI, 
      Instituto Mexicano del Seguro Social and Departamento de Investigacion, Hospital 
      Infantil de Mexico Federico Gomez, Secretaria de Salud, Mexico City, Mexico.
FAU - Manuel Gallardo, Juan
AU  - Manuel Gallardo J
AD  - Unidad de Investigacion Medica en Enfermedades Nefrologicas, Hospital de 
      Especialidades Dr. Bernardo Sepulveda, Centro Medico Nacional Siglo XXI, 
      Instituto Mexicano del Seguro Social, Mexico City, Mexico.
FAU - Estrada-Cruz, Norma A
AU  - Estrada-Cruz NA
AD  - Unidad de Investigacion Medica en Farmacologia, Hospital de Especialidades Dr. 
      Bernardo Sepulveda, Centro Medico Nacional Siglo XXI, Instituto Mexicano del 
      Seguro Social, Mexico City, Mexico.
FAU - Camacho-Arroyo, Ignacio
AU  - Camacho-Arroyo I
AD  - Unidad de Investigacion en Reproduccion Humana, Instituto Nacional de 
      Perinatologia-Facultad de Quimica, Universidad Nacional Autonoma de Mexico, 
      Mexico City, Mexico.
FAU - Guerra-Araiza, Christian
AU  - Guerra-Araiza C
AD  - Unidad de Investigacion Medica en Farmacologia, Hospital de Especialidades Dr. 
      Bernardo Sepulveda, Centro Medico Nacional Siglo XXI, Instituto Mexicano del 
      Seguro Social, Mexico City, Mexico. Electronic address: 
      christianguerra2001@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200906
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (Dietary Carbohydrates)
RN  - 0 (Estrogen Receptor Modulators)
RN  - 0 (Norpregnenes)
RN  - 0 (Receptors, Androgen)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 30237-26-4 (Fructose)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
RN  - EC 2.7.10.1 (Receptor, Insulin)
RN  - FF9X0205V2 (tibolone)
SB  - IM
MH  - Animals
MH  - *Diet, High-Fat
MH  - *Dietary Carbohydrates
MH  - Estrogen Receptor Modulators/*pharmacology
MH  - Female
MH  - Frontal Lobe/drug effects/*metabolism
MH  - Fructose
MH  - Hippocampus/drug effects/*metabolism
MH  - Hypothalamus/drug effects/*metabolism
MH  - Norpregnenes/*pharmacology
MH  - Ovariectomy
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptor, IGF Type 1/metabolism
MH  - Receptor, Insulin/metabolism
MH  - Receptors, Androgen/metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
OTO - NOTNLM
OT  - Hormone receptors
OT  - Hormone replacement therapy
OT  - Menopause
OT  - Metabolic syndrome
OT  - Tibolone
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/09/09 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/09/08 20:07
PHST- 2020/04/20 00:00 [received]
PHST- 2020/08/26 00:00 [revised]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/09/08 20:07 [entrez]
AID - S0006-8993(20)30454-6 [pii]
AID - 10.1016/j.brainres.2020.147096 [doi]
PST - ppublish
SO  - Brain Res. 2020 Dec 1;1748:147096. doi: 10.1016/j.brainres.2020.147096. Epub 2020 
      Sep 6.